Medulloblastoma clinical trials

Explore recruiting medulloblastoma clinical trials.

Recruiting medulloblastoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Medulloblastoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY

Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

MEPENDAX: Phase I/II study of axitinib (Inlyta®) and oral metronomic etoposide for pediatric children and AYA with refractory/relapsing medulloblastoma and ependymoma

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

EORTC 1634-BTG (NOA-23): Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

An International Prospective Study in Children Older than 3 to 5 Years with Clinically Standard-Risk Medulloblastoma with Low-Risk Biological Profile (PNET 5 MB – LR and PNET 5 MB – WNT-HR), average-risk biological profile (PNET 5 MB -SR), or TP53 mutation, and registry for MB ocurring in the context of genetic predisposition

Spain, Netherlands, Czechia, Sweden, Belgium, Finland +4 more

Phase II and Phase III (Integrated) EU CTIS Study details

An interventional, open-label, Phase II study, to evaluate safety and efficacy of standard and high-dose chemotherapy associated with craniospinal irradiation in patients with metastatic medulloblastoma and other embryonal tumours

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Chemotherapy for the treatment of standard risk adult medulloblastomas

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Medulloblastoma trials by city

Medulloblastoma in Toronto Medulloblastoma in Vancouver Medulloblastoma in Montreal Medulloblastoma in Calgary Medulloblastoma in Edmonton Medulloblastoma in Ottawa Medulloblastoma in Winnipeg Medulloblastoma in Quebec City Medulloblastoma in Hamilton Medulloblastoma in Kitchener Medulloblastoma in London Medulloblastoma in Halifax Medulloblastoma in New York Medulloblastoma in Los Angeles Medulloblastoma in Chicago Medulloblastoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease